225 related articles for article (PubMed ID: 29104473)
1. The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.
Lin HC; Yang CJ; Kuan YD; Wang WK; Chang WW; Lee CH
Int J Med Sci; 2017; 14(12):1181-1188. PubMed ID: 29104473
[TBL] [Abstract][Full Text] [Related]
2. Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2, 3-dioxygenase 1 expression.
Kuan YD; Lee CH
Oncotarget; 2016 Jan; 7(1):374-85. PubMed ID: 26517244
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
[TBL] [Abstract][Full Text] [Related]
4. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape.
Katz JB; Muller AJ; Prendergast GC
Immunol Rev; 2008 Apr; 222():206-21. PubMed ID: 18364004
[TBL] [Abstract][Full Text] [Related]
6. The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.
Brochez L; Chevolet I; Kruse V
Eur J Cancer; 2017 May; 76():167-182. PubMed ID: 28324751
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation.
Munn DH
Curr Opin Immunol; 2006 Apr; 18(2):220-5. PubMed ID: 16460921
[TBL] [Abstract][Full Text] [Related]
8. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
9. Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.
Zheng X; Koropatnick J; Li M; Zhang X; Ling F; Ren X; Hao X; Sun H; Vladau C; Franek JA; Feng B; Urquhart BL; Zhong R; Freeman DJ; Garcia B; Min WP
J Immunol; 2006 Oct; 177(8):5639-46. PubMed ID: 17015752
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies.
Selvan SR; Dowling JP; Kelly WK; Lin J
Curr Cancer Drug Targets; 2016; 16(9):755-764. PubMed ID: 26517538
[TBL] [Abstract][Full Text] [Related]
11. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA.
Yen MC; Lin CC; Chen YL; Huang SS; Yang HJ; Chang CP; Lei HY; Lai MD
Clin Cancer Res; 2009 Jan; 15(2):641-9. PubMed ID: 19147770
[TBL] [Abstract][Full Text] [Related]
12. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.
Muller AJ; Malachowski WP; Prendergast GC
Expert Opin Ther Targets; 2005 Aug; 9(4):831-49. PubMed ID: 16083346
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase.
Noh KT; Chae SH; Chun SH; Jung ID; Kang HK; Park YM
Biochem Biophys Res Commun; 2013 Feb; 431(2):348-53. PubMed ID: 23291179
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H; Mediavilla-Varela M; Antonia S
Cancer J; 2010; 16(4):354-9. PubMed ID: 20693847
[TBL] [Abstract][Full Text] [Related]
16. The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells.
Wang XF; Wang HS; Wang H; Zhang F; Wang KF; Guo Q; Zhang G; Cai SH; Du J
Cell Immunol; 2014; 289(1-2):42-8. PubMed ID: 24721110
[TBL] [Abstract][Full Text] [Related]
17. The extracts of
Phacharapiyangkul N; Wu LH; Lee WY; Kuo YH; Wu YJ; Liou HP; Tsai YE; Lee CH
Int J Med Sci; 2019; 16(8):1107-1115. PubMed ID: 31523173
[No Abstract] [Full Text] [Related]
18. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.
von Bergwelt-Baildon MS; Popov A; Saric T; Chemnitz J; Classen S; Stoffel MS; Fiore F; Roth U; Beyer M; Debey S; Wickenhauser C; Hanisch FG; Schultze JL
Blood; 2006 Jul; 108(1):228-37. PubMed ID: 16522817
[TBL] [Abstract][Full Text] [Related]
19. Targeted siRNA silencing of indoleamine 2, 3-dioxygenase in antigen-presenting cells using mannose-conjugated liposomes: a novel strategy for treatment of melanoma.
Chen D; Koropatnick J; Jiang N; Zheng X; Zhang X; Wang H; Yuan K; Siu KS; Shunnar A; Way C; Min WP
J Immunother; 2014; 37(2):123-34. PubMed ID: 24509175
[TBL] [Abstract][Full Text] [Related]
20. Uveal melanoma expression of indoleamine 2,3-deoxygenase: establishment of an immune privileged environment by tryptophan depletion.
Chen PW; Mellon JK; Mayhew E; Wang S; He YG; Hogan N; Niederkorn JY
Exp Eye Res; 2007 Nov; 85(5):617-25. PubMed ID: 17870068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
